Near future
No Result
View All Result
December 4 2023
  • Home
  • Tech
  • Healthcare
  • Ambiente
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+
News about the world of tomorrow.
CES2023 / Coronavirus / Russia-Ukraine
Near future
  • Home
  • Tech
  • Healthcare
  • Ambiente
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+

News about the world of tomorrow.

No Result
View All Result
Medicine

Alopecia, a new US drug treats 40% of patients: the FDA asked for ok

A new alopecia drug shows impressive results. Here are the updates from phase three of the trial

May 29, 2022
Gianluca RiccioGianluca Riccio
⚪ 4 minutes
Share405Pin93Tweet253SendShare71ShareShare51
alopecia drug

Follow the Futuro Prossimo Whatsapp Channel! Daily updates and extra content.

Sign up for free

I foresee a rain of money in the sector of hair loss: Researchers have developed a drug that can potentially treat alopecia, a major cause of the problem.

We are always a bit skeptical when it comes to these remedies: studies and research of all kinds have been circulating for years, but progress often seems slow and inconstant. Even the best remedies often lead to regression.

But this seems like a significant advance: it is a pill, to be taken twice a day, that reverses the fall. Studies on the drug show that in 40% of patients over 80% of lost hair regrows within 12 months.

CTP-543, this is the name of the drug, aims to reverse the effects of alopecia areata, which causes the body to attack its own hair follicles.

The article continues after the related links

Latex, platform that simulates 8 organs for drug testing

Goodbye needles: drugs from the cheeks through mini patches inspired by octopuses

alopecia

Alopecia, a relentless scourge

It affects 2% of the entire world population. The male average is around 39%, but everyone is affected: men and women. Alopecia is a condition that, apart from the aesthetic factor, can also cause psychological effects such as severe depression.

(I leave out the story of the episode during the night of the Oscars, you all know what I'm talking about).

This week, the company producing the drug has released updates on phase three of the trial, defining the results as "a milestone" in the treatment of alopecia.

"There is a great need for treatments for this difficult disease and the results of the THRIVE-AA1 study suggest that CTP-543 could provide an important therapy for the treatment of alopecia areata."

How does the new alopecia drug work?

CTP-543 inhibits the enzymes involved in the effects of alopecia: these are the Janus kinase enzymes, or JAK1 and JAK2. When too many of these enzymes are present, the inflammatory immune response causes hair loss. 

Patients saw significant hair regrowth during the studies. The last monitored 706 adults with alopecia, aged between 18 and 65, for 24 weeks in the US, Canada and Europe. On average, the patients studied had only 16% of their hair at the beginning of the study: none of them had more than 50%.

The patients were divided into three groups: one was given a placebo, another was given an 8-milligram dose twice a day, and finally a 12-milligram pill twice a day.

Both groups who took doses of the anti-alopecia drug saw regrowth, with a total of 41,5% of the recipients of the strongest dose who have experienced the80% of hair regrowth. Among those who received the lowest dose, almost 30% experienced the same amount of hair regrowth. In the placebo group, only 0,8% of the participants saw more than 80% of hair growth. Patients saw the greatest regrowth with the strongest dosage.

È sicuro?

The pharmaceutical group says the anti-alopecia drug is "generally well tolerated": less than 5% of patients complain of headaches, acne and other minor side effects.

After repeating the phase three study again in 517 other patients, the company wants to present its results and apply for approval from the U.S. Food and Drug Administration next year.

"We are extremely grateful to the patients and teams of clinical research professionals who participate in our studies," King said in the statement. "We are working to change the landscape of alopecia treatment, and we hope that CTP-543 will be one of the first treatment options approved by the FDA."

It should be said: Hope grows again :)

Tags: alopeciabaldnesshairdrugs


GPT Chat Megaeasy!

Concrete guide for those approaching this artificial intelligence tool, also designed for the school world: many examples of applications, usage indications and ready-to-use instructions for training and interrogating Chat GPT.

To submit articles, disclose the results of a research or scientific discoveries write to the editorial staff

Latest news

Traumatic brain injuries, EyeD can save your life in minutes

Cerabyte, the incredible ceramic memory: 10.000TB in one hand

The "dream" of robotic pizza fails: half a billion dollar collapse

No-Kids, more and more people choose life without children (and regrets)

The EU is making a big push for the cleanest energy in the world

Prophetic, the startup that wants to make us work even in our sleep

Blue zones: do they really exist or are we wrong?

Goodbye neonatal test: will children be born with their genetic future already written?

Anthrobots, human cells transformed into robots that heal wounds

Deepmind AI, an 800-year leap forward in materials science

Office? No thank you! Remote work is here to outlive us

Roadrunner, incredible vertical take-off autonomous anti-aircraft drone

Follow us on the Futuroprossimo channels! We're up Telegram, Whatsapp, Instagram, Facebook, Twitter, Mastodon, Analysis.

FacebookTwitterInstagramTelegramAnalysisMastodonPinterestTikTok

The daily tomorrow.


Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

  • Ambiente
  • Architecture
  • Artificial intelligence
  • Gadgets
  • concepts
  • Design
  • Medicine
  • Spazio
  • Robotica
  • Work
  • Transports
  • Energy
  • Edition Francaise
  • Deutsche Ausgabe
  • Japanese version
  • English Edition
  • Portuguese Edition
  • Read more
  • Spanish edition

Subscribe to our newsletter

  • The Editor
  • Advertising on FP
  • Privacy Policy

© 2023 Near future - Creative Commons License
This work is distributed under license Creative Commons Attribution 4.0 International.

No Result
View All Result
News about the world of tomorrow.
  • Home
  • Tech
  • Healthcare
  • Ambiente
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+